Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextromethorphan + phenylephrine is an oral combination pharmaceutical product used primarily for the **temporary relief of cough and nasal congestion** associated with the common cold, flu, and upper respiratory tract infections. - **Dextromethorphan** is a non-opioid antitussive (cough suppressant) that acts centrally on the cough center in the medulla oblongata to reduce the cough reflex, without the analgesic or addictive properties associated with opioid cough suppressants. - **Phenylephrine** is a sympathomimetic decongestant that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction in nasal mucosa to decrease swelling and congestion. This combination does not treat the underlying infection or cause of symptoms, but provides symptomatic relief. It is available over-the-counter in various formulations, sometimes as part of multi-ingredient cough/cold preparations[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextromethorphan + phenylephrine.